---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000038"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:13:57.780171+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Novocure Q1 2023: Revenue down 11% to $122M, net loss $53.1M, prescriptions up 8%

## Summary
- Total net revenues $122.2M (-11% YoY); US $85.2M, Germany $15.1M, Japan $8.7M.
- Net loss $53.1M ($0.50 loss per share); adjusted EBITDA -$18.4M.
- Prescriptions received 1,496 (+8% YoY); active patients 3,467 as of March 31.
- R&D expenses +41% to $59.7M on clinical trial activity; sales & marketing +35%.
- Phase 3 LUNAR NSCLC data to be presented at ASCO June 6; METIS enrollment completed, data Q1 2024.

## SEC filing metadata
- accession: 0001645113-23-000038
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/0001645113-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/nvcr-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000038
- JSON: https://secwatch.observer/filing/0001645113-23-000038.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000038.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported quarter ended March 31, 2023 results: revenue $122.2 million, net income $53.1 million, EPS $0.50.
  - Period: quarter ended March 31, 2023
  - Revenue: $122.2 million
  - Net income: $53.1 million
  - EPS: $0.50
  - Result: reported results
  source text: Financial updates for the first quarter ended March 31, 2023: • Total net revenues for the quarter were $122.2 million, a decrease of 11% compared to the same period in 2022. ◦ The United States, Germany and Japan contributed $85.2 million, $15.1 million and $8.7 million in quarterly net revenues, respectively, with our other active markets contributing $7.9 million. ◦ Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $5.3 million. • Gross margin for the quarter was 76%. • Research, development and clinical studies expenses for the quarter were $59.7 million, an increase of 41% from the same period in 2022. This primarily reflects increased clinical trial and personnel costs associated with the PANOVA-3 and METIS clinical trials. Total clinical trial expenses can fluctuate quarter-to-quarter dependent upon the amount of clinical research organization services delivered, clinical materials procured and number of trials actively underway. • Sales and marketing exp
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/0001645113-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.